Nashville-based Cumberland Pharmaceuticals recently announced the launch of Caldolor® (ibuprofen) injection for pediatric patients. This launch follows the U.S. Food and Drug Administration approval of Caldolor for the treatment of pain and fever in children six months of age and older. Caldolor is an injectable form of ibuprofen designed primarily for hospitalized patients who are not able to tolerate their pain and fever medications orally. It is the first and only injectable non-steroidal anti-inflammatory drug (NSAID) approved for the treatment of pain and fever in pediatric patients.
The recommended dosing of Caldolor is 10mg/kg for children ages 6 months to 12 years every four to six hours as necessary, with a maximum dose of 400mg. For children ages 12 to 17 years of age, the recommend dosing of Caldolor is 400mg every four to six hours as necessary to manage the patient’s pain or fever. Caldolor is diluted and administered intravenously over a 10-minute infusion and the maximum daily dose in pediatric patients is 2,400 mg.